Skip to main content

Table 3 Cytokines and Growth Factors Altered by RT and FG-3019

From: Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab

  18w Fc vs noRT 30w Fc vs noRT
Gene ID Description RT RT + FG RT RT + FG
Chemokines (Chemotaxis)
 Cxcl9 chemokine (C-X-C motif) ligand 9 79.8 4.0 1.1 0.5
 Ccl8 chemokine (C-C motif) ligand 8 (MCP-2) 29.0 2.0 5.4 0.9
 Cxcl10 chemokine (C-X-C motif) ligand 10 17.2 1.5 1.0 0.5
 Ccl1 chemokine (C-C motif) ligand 1 8.9 2.1 2.9 1.2
 Ccl12 chemokine (C-C motif) ligand 12 (MCP-5) 8.3 0.6 1.9 0.7
 Ccl7 chemokine (C-C motif) ligand 7 (MCP-3) 7.9 0.6 1.3 0.5
 Ccl2 chemokine (C-C motif) ligand 2 (MCP-1) 7.3 0.6 1.1 0.5
 Ccl3 chemokine (C-C motif) ligand 3 (MIP-1a) 6.9 0.8 1.3 0.4
 Ccl6 chemokine (C-C motif) ligand 6 5.8 0.7 2.8 1.1
 Ccl9 chemokine (C-C motif) ligand 9 (MIP-1 g) 5.7 0.8 2.2 1.0
 Ccl5 chemokine (C-C motif) ligand 5 (RANTES) 3.9 1.7 0.9 0.8
 Ccl17 chemokine (C-C motif) ligand 17 3.7 1.1 0.9 0.7
 Ccl4 chemokine (C-C motif) ligand 4 (MIP-1 p) 3.6 1.4 0.9 0.6
 Cxcl1 chemokine (C-X-C motif) ligand 1 2.4 0.6 0.7 0.5
 Cxcl16 chemokine (C-X-C motif) ligand 16 2.3 0.7 1.4 0.9
 Cxcl12 chemokine (C-X-C motif) ligand 12 (SDF-1) 2.2 0.5 1.4 1.1
 Cxcl3 chemokine (C-X-C motif) ligand 3 (MIP-2p) 2.0 0.5 2.2 0.7
Cytokines (Cell Activation)
 Tnfsf18 tumor necrosis factor (ligand) superfamily, member 18 46.8 3.6 2.8 1.0
 Il1rn interleukin 1 receptor antagonist 5.7 1.2 1.8 0.7
 Il6 interleukin 6 4.7 1.0 1.7 0.6
 Il12b interleukin 12b 4.7 1.6 0.9 0.8
 Tnfsf8 tumor necrosis factor (ligand) superfamily, member 8 4.4 1.6 1.9 1.1
 C1qtnf9 C1q and tumor necrosis factor related protein 9 3.8 1.7 2.6 1.2
 C1qtnf5 C1q and tumor necrosis factor related protein 5 2.5 1.0 1.7 1.2
 Il18 interleukin 18 2.4 0.6 1.6 1.0
 Il4 interleukin 4 2.4 1.7 0.9 0.7
 Il12a interleukin 12a 0.5 1.1 0.6 1.4
TGFβ / BMP Signaling (Differentiation, Migration, ECM Production,...)
 Gdf3 growth differentiation factor 3 32.1 3.9 4.2 1.1
 Inhba inhibin beta-A 7.8 1.1 1.9 1.2
 Gdf6 growth differentiation factor 6 (BMP13) 5.9 0.6 3.7 1.8
 Fst follistatin 5.7 0.8 1.5 1.1
 Grem1 gremlin 1 4.7 1.8 1.5 0.8
 Gdf15 growth differentiation factor 15 4.0 1.7 3.0 2.6
 Fstl1 follistatin-like 1 4.0 1.0 2.4 1.3
 Ltbp2 latent transforming growth factor beta binding protein 2 3.9 1.0 2.1 1.3
 Ctgf connective tissue growth factor 3.5 1.1 1.2 0.8
 Bmp8a bone morphogenetic protein 8a 2.8 1.2 1.9 1.5
 Bmp6 bone morphogenetic protein 6 0.2 0.3 0.4 0.7
Wnt Signaling (Cell Polarity, Pattern Formation)
 Wnt10a wingless related MMTV integration site 10a 22.1 1.1 2.3 1.1
 Frzb frizzled-related protein 8.5 1.2 2.2 0.9
 Sfrp1 secreted frizzled-related protein 1 6.3 0.6 3.2 1.0
 Wisp1 WNT1 inducible signaling pathway protein 1 5.3 0.9 2.4 1.5
 Wisp2 WNT1 inducible signaling pathway protein 2 4.0 0.9 2.7 1.3
 Fzd2 frizzled homolog 2 (Drosophila) 2.8 0.9 1.8 1.2
 Wnt7a wingless-related MMTV integration site 7A 2.7 1.2 1.3 0.9
 Fzd7 frizzled homolog 7 (Drosophila) 2.0 0.8 1.5 0.8
IGF Signaling (Proliferation, Survival)
 Insl6 insulin-like 6 7.9 1.4 3.1 1.2
 Igf1 insulin-like growth factor 1 6.3 0.7 4.7 1.3
 Igfbp2 insulin-like growth factor binding protein 2 3.5 0.8 1.9 1.6
 Igfbp4 insulin-like growth factor binding protein 4 2.6 1.4 1.5 1.1
 Igfbp7 insulin-like growth factor binding protein 7 2.5 0.7 1.5 1.2
 Igfbp6 insulin-like growth factor binding protein 6 0.3 0.6 0.6 0.9
Other Cytokines & Growth Factors
 Retnla resistin like alpha 10.5 1.7 6.4 1.4
 Angptl7 angiopoietin-like 7 5.0 1.4 1.0 1.0
 Pdgfc platelet-derived growth factor, C polypeptide 4.2 0.4 1.5 1.0
 Csf3 colony stimulating factor 3 (G-CSF) 3.3 2.3 1.4 1.1
 Angptl3 angiopoietin-like 3 3.2 1.2 1.8 1.3
 Fgf2 fibroblast growth factor 2 2.5 1.3 1.4 0.9
 Pdgfd platelet-derived growth factor, D polypeptide 2.2 0.9 1.9 1.4
 Pgf placental growth factor 2.1 0.9 1.1 0.8
 Fgfbp1 fibroblast growth factor binding protein 1 0.4 0.6 0.7 1.1
 Cytl1 cytokine-like 1 0.3 1.0 0.4 0.7
 Retn resistin 0.2 1.2 0.2 0.3
  1. Fold-change (Fc) values are relative to unirradiated (noRT) controls for RT alone and RT + FG-3019 (FG) treatment begun 16 weeks after RT